PS2 - 172 Preclinical Validation of a Novel CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody to Target Patient-Derived Glioblastoma Cells

Canadian Journal of Neurological Sciences - United Kingdom
doi 10.1017/cjn.2016.367
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cambridge University Press (CUP)

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy